Safety
fracture, anemia, fatigue, arthralgia
ADVERSE EVENT, ANEMIA, HYPERCALCEMIA
The most common AEs (any grade) were hypercalcemia, arthralgia, fatigue, and anemia (AEs occurring in ≥20% of all patients.Data are Abbreviations: AE, adverse event; SAE, serious adverse event.A phase II study was planned to assess the clinical efficacy and further safety of the treatment combination. However, enrollment was halted in April 2016 prior to initiation of phase II due to the emergence of 6 reported serious AEs of bone fracture across multiple studies involving WNT974. The preliminary efficacy data of the triplet combination (WNT974 + encorafenib + cetuximab) demonstrated limited improvement in clinical activity relative to the efficacy observed with doublet treatment (encorafenib + cetuximab) in patients with 